Smith & Nephew - SNN Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$25.31
▼ -0.37 (-1.44%)

This chart shows the closing price for SNN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Smith & Nephew Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SNN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SNN

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for Smith & Nephew in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $25.31.

This chart shows the closing price for SNN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 investment analysts is to moderate buy stock in Smith & Nephew. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/22/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/22/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/20/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/18/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/17/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/16/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/15/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/14/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/5/2024UBS GroupUpgradeNeutral ➝ BuyLow
11/28/2023BarclaysUpgradeUnderweight ➝ Equal WeightLow
11/3/2023JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightLow
10/31/2023HSBCUpgradeHold ➝ BuyLow
10/13/2023Stifel NicolausInitiated CoverageHoldLow
8/8/2023UBS GroupUpgradeSell ➝ NeutralLow
4/27/2023HSBCDowngradeBuy ➝ HoldLow
4/11/2023Morgan StanleyUpgradeEqual Weight ➝ OverweightLow
3/29/2023BarclaysDowngradeOverweight ➝ UnderweightLow
3/7/2023Sanford C. BernsteinInitiated CoverageOutperformLow
3/1/2023Liberum CapitalUpgradeHold ➝ BuyLow
2/22/2023UBS GroupBoost TargetGBX 970 ➝ GBX 1,000Low
2/22/2023BarclaysLower TargetGBX 1,500 ➝ GBX 1,480Low
2/16/2023Liberum CapitalInitiated CoverageHoldLow
12/12/2022CitigroupInitiated CoverageBuyLow
11/28/2022UBS GroupDowngradeNeutral ➝ SellLow
10/18/2022Morgan StanleyInitiated CoverageEqual WeightLow
10/4/2022BarclaysLower TargetGBX 1,550 ➝ GBX 1,530Low
8/16/2022UBS GroupLower TargetGBX 1,190 ➝ GBX 1,116Low
7/28/2022Canaccord Genuity GroupDowngradeBuy ➝ HoldLow
7/5/2022BarclaysLower TargetGBX 1,650 ➝ GBX 1,630N/A
5/31/2022BarclaysLower TargetGBX 1,680 ➝ GBX 1,650High
4/29/2022UBS GroupBoost TargetGBX 1,200 ➝ GBX 1,295Low
3/15/2022Royal Bank of CanadaInitiated CoverageOutperformLow
3/4/2022Redburn PartnersUpgradeSell ➝ NeutralMedium
3/2/2022JPMorgan Chase & Co.Boost TargetGBX 1,376 ➝ GBX 1,442High
11/5/2021JPMorgan Chase & Co.Reiterated RatingNeutralLow
10/4/2021Berenberg BankReiterated RatingBuyLow
9/30/2021BarclaysReiterated RatingOverweightMedium
9/10/2021BarclaysReiterated RatingOverweightLow
8/17/2021Morgan StanleyReiterated RatingOverweightLow
8/2/2021JPMorgan Chase & Co.Reiterated RatingNeutralLow
7/1/2021BarclaysReiterated RatingOverweightLow
6/9/2021Credit Suisse GroupUpgradeNeutral ➝ OutperformLow
5/28/2021JPMorgan Chase & Co.Reiterated RatingNeutralLow
5/4/2021Berenberg BankReiterated RatingBuyMedium
5/4/2021Credit Suisse GroupReiterated RatingNeutralMedium
4/30/2021BarclaysReiterated RatingOverweightLow
3/31/2021BarclaysReiterated RatingOverweightLow
2/23/2021Berenberg BankReiterated RatingBuyLow
2/22/2021JPMorgan Chase & Co.Reiterated RatingNeutralMedium
2/22/2021Credit Suisse GroupReiterated RatingNeutralMedium
2/22/2021CommerzbankDowngradeBuy ➝ HoldLow
1/22/2021JPMorgan Chase & Co.Reiterated RatingNeutralLow
1/21/2021BarclaysReiterated RatingOverweightLow
1/20/2021Berenberg BankReiterated RatingBuyMedium
12/18/2020JPMorgan Chase & Co.Reiterated RatingNeutralLow
12/18/2020Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$46.50Medium
12/9/2020Morgan StanleyReiterated RatingOverweightLow
12/1/2020BarclaysInitiated CoverageOverweightLow
10/30/2020JPMorgan Chase & Co.Reiterated RatingNeutralLow
7/31/2020Berenberg BankReiterated RatingBuyLow
7/30/2020JPMorgan Chase & Co.Reiterated RatingNeutralMedium
7/30/2020Morgan StanleyReiterated RatingOverweightHigh
7/29/2020Bank of AmericaUpgradeNeutral ➝ BuyLow
7/10/2020Berenberg BankReiterated RatingBuyLow
6/5/2020BNP ParibasDowngradeNeutral ➝ UnderperformLow
6/5/2020Exane BNP ParibasDowngradeNeutral ➝ UnderperformLow
6/4/2020Morgan StanleyUpgradeEqual Weight ➝ OverweightLow
5/11/2020Berenberg BankReiterated RatingBuyLow
5/7/2020JPMorgan Chase & Co.Reiterated RatingNeutralLow
5/7/2020CfraLower TargetHold$52.00 ➝ $42.00Low
4/14/2020CitigroupDowngradeBuy ➝ NeutralMedium
3/31/2020JPMorgan Chase & Co.Reiterated RatingNeutralLow
2/21/2020CfraBoost TargetHold$46.00 ➝ $52.00Medium
11/21/2019CitigroupInitiated CoverageBuyLow
11/12/2019Sanford C. BernsteinInitiated CoverageOutperformLow
7/23/2019Berenberg BankUpgradeHold ➝ BuyLow
(Data available from 6/14/2019 forward)

News Sentiment Rating

1.12 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/17/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/17/2023
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/16/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/15/2024
  • 12 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/16/2024
  • 4 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/15/2024
  • 8 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
5/15/2024
  • 8 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/14/2024

Current Sentiment

  • 8 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Smith & Nephew logo
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Read More

Today's Range

Now: $25.31
Low: $25.15
High: $25.33

50 Day Range

MA: $24.99
Low: $23.78
High: $26.48

52 Week Range

Now: $25.31
Low: $21.52
High: $32.28

Volume

497,877 shs

Average Volume

957,378 shs

Market Capitalization

$11.06 billion

P/E Ratio

N/A

Dividend Yield

3.49%

Beta

0.8

Frequently Asked Questions

What sell-side analysts currently cover shares of Smith & Nephew?

The following Wall Street sell-side analysts have issued stock ratings on Smith & Nephew in the last twelve months: Barclays PLC, HSBC Holdings plc, JPMorgan Chase & Co., Stifel Nicolaus, StockNews.com, and UBS Group AG.
View the latest analyst ratings for SNN.

What is the current price target for Smith & Nephew?

0 Wall Street analysts have set twelve-month price targets for Smith & Nephew in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Smith & Nephew in the next year.
View the latest price targets for SNN.

What is the current consensus analyst rating for Smith & Nephew?

Smith & Nephew currently has 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for SNN.

What other companies compete with Smith & Nephew?

Other companies that are similar to Smith & Nephew include Zimmer Biomet, STERIS, Align Technology, MSA Safety and Enovis. Learn More about companies similar to Smith & Nephew.

How do I contact Smith & Nephew's investor relations team?

Smith & Nephew's physical mailing address is BUILDING 5 CROXLEY PARK HATTERS LANE, WATFORD X0, WD18 8YE. The medical equipment provider's listed phone number is 441923477100 and its investor relations email address is [email protected]. The official website for Smith & Nephew is www.smith-nephew.com. Learn More about contacing Smith & Nephew investor relations.